|
1
|
Ozawa S, Tachimori Y, Baba H, Matsubara H,
Muro K, Numasaki H, Oyama T, Shinoda M, Takeuchi H, Tanaka O, et
al: Comprehesive registry of esophageal cancer in Japan, 2002.
Esophagus. 7:7–22. 2010. View Article : Google Scholar
|
|
2
|
Li H, Zhang Y, Cai H and Xiang J: Pattern
of lymph node metastases in patients with squamous cell carcinoma
of the thoracic esophagus who underwent three-field
lymphadenectomy. Eur Surg Res. 39:1–6. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Igaki H, Tachimori Y and Kato H: Improved
survival for patients with upper and/or middle mediastinal lymph
node metastasis of squamous cell carcinoma of the lower thoracic
esophagus treated with 3-field dissection. Ann Surg. 239:483–490.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fujita H, Sueyoshi S, Tanaka T and
Shirouzu K: Three-field dissection for squamous cell carcinoma in
the thoracic esophagus. Ann Thorac Cardiovasc Surg. 8:328–335.
2002.PubMed/NCBI
|
|
5
|
Shimada Y, Imamura M, Sato F, Maeda M,
Kaganoi J, Hashimoto Y, Kan T, Nagatani S and Li Z: Indications for
abdominal para-aortic lymph node dissection in patients with
esophageal squamous cell carcinoma. Surgery. 132:93–99. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ye K, Xu JH, Sun YF, Lin JA and Zheng ZG:
Characteristics and clinical significance of lymph node metastases
near the recurrent laryngeal nerve from thoracic esophageal
carcinoma. Genet Mol Res. 13:6411–6419. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Katada N, Yamashita K, Katada C, Moriya H,
Hosoda K, Mieno H, Higuchi K, Komori S, Ishiyama H, Hayakawa K, et
al: Neoadjuvant chemotherapy using concurrent Docetaxel/CDDP/5-FU
(DCF) in esophageal squamous cell carcinoma and its short-term
prognosis. Esophagus. 11:173–181. 2014. View Article : Google Scholar
|
|
8
|
Yamashita K, Katada N, Moriya H, Hosoda K,
Mieno H, Katada C, Koizumi W, Hoshi K and Watanabe M: Neoadjuvant
chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF
NAC) may improve patient prognosis of cStage II/III esophageal
squamous cell carcinoma-propensity score analysis. Gen Thorac
Cardiovasc Surg. 64:209–215. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Japanese Society for Esophageal Disease:
Guideline for the clinical and pathological studies on carcinoma of
the esophagus. 10th edition. revised. Kanehara & Co., Ltd;
Tokyo: 2002
|
|
10
|
Nishimaki T, Suzuki T, Tanaka Y, Nakagawa
S, Aizawa K and Hatakeyama K: Evaluating the rational extent of
dissection in radical esophagectomy for invasive carcinoma of the
thoracic esophagus. Surg Today. 27:3–8. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Motoyama S, Kitamura M, Saito R, Maruyama
K, Okuyama M and Ogawa J: Outcome and treatment strategy for mid-
and lower-thoracic esophageal cancer recurring locally in the lymph
nodes of the neck. World J Surg. 30:191–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamashita K, Hosoda K, Moriya H, Katada C,
Sugawara M, Mieno H, Komori S, Katada N and Watanabe M: Prognostic
advantage of docetaxel/cisplatin/ 5-fluorouracil neoadjuvant
chemotherapy in clinical stage II/III esophageal squamous cell
carcinoma due to excellent control of preoperative disease and
postoperative lymph node recurrence. Oncology. 92:221–228. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tachimori Y, Ozawa S, Numasaki H, Ishihara
R, Matsubara H, Muro K, Oyama T, Toh Y, Udagawa H and Uno T:
Registration Committee for Esophageal Cancer of the Japan
Esophageal Society: Comprehensive registry of esophageal cancer in
Japan, 2010. Esophagus. 14:189–214. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang HX, Hou X, Liu QW, Zhang LJ, Liu JG,
Lin P and Fu JH: Tumor location does not impact long-term survival
in patients with operable thoracic esophageal squamous cell
carcinoma in China. Ann Thorac Surg. 93:1861–1866. 2012. View Article : Google Scholar : PubMed/NCBI
|
